For the Hospital OQR, REHQR, and ASCQR Programs, at 419.46(e)(2)(ii), 419.95(g)(2)(ii), and 416.310(d)(2)(ii), respectively, we proposed that CMS would notify the requestor with a decision in writing
In the STEP1 involved 1,961 participants with obesity or overweight, 68-week treatment of semaglutide 2.4 mg demonstrated an average weight reduction of 14.9% [16]
Some compounded versions may have shorter or longer out-of-fridge stability windows
Without that paper trail, eligibility becomes far harder to establish after the fact
However, expecting lifestyle alone to maintain medication-induced weight loss misaligns with current metabolic science
The most important factor is consistency and adherence to the prescribed regimen, with timing adjusted to suit individual lifestyle, side effect patterns, and clinical needs